Carl Freer | |
---|---|
![]() Freer in February 2012 | |
Born | Carl Johan Freer |
Nationality | Swedish |
Occupation(s) | Entrepreneur, businessman |
Carl Johan Freer is a Swedish businessman and technology entrepreneur primarily known for founding the American company Tiger Telematics, which created the handheld game console Gizmondo. [1] [2] Freer is also the founder of Singapore-based medical-device company, Aluminaid and co-author of several patents. [3] [4]
The earlier part of Carl’s career was focused on disruptive software companies. [5] Freer founded Tiger Telematics, an electronics company that launched in 2002, raised over £160 million, and reached a market cap over $1 billion [6] before it dissolved in 2006. [7] He managed the development, launch and promotion of the Gizmondo. Freer was Chairman of the Tiger Telematics board of directors until he resigned [8] in October 2005 pending publication of an article in the Swedish press. [9] [10] By 6 February 2006, the company was forced into compulsory liquidation and Gizmondo was discontinued. [11] [12]
Other ventures included Xero Mobile—which had a service that automatically billed advertisers based on the number of marketing messages viewed by users—and Getfugu, which developed an application that enabled consumers to retrieve web content without typing a website address or search term into a browser. [13] [14] Freer co-founded a crowdsourcing networking website for filmmakers, financiers, actors and fans called FilmFunds as well as the Family Tree Foundation. [15] [16] [17]
In 2008, Carl Freer hosted a seminar at Georgia Institute of Technology entitled "High Tech Ventures in Mobile Gaming and Media". Freer discussed his experiences, his plans for a potential rebirth of Gizmondo as well as his plans for the development of new mobile video technologies. The event took place as part of GA Tech's GVU Center Lecture series. [18] [19] [20] Later that year, a relaunch of Gizmondo was aborted. [21] In 2010, Freer co-founded Aluminaid, which makes metal-based bandages to relieve pain in patients with first- and second-degree burns. [4]
Freer is from a computational science background focusing on the biotech domain. In 2008, he, along with Richard Grossman and Tom Brady, founded Aluminaid, a medical device company that developed a patented burn dressing. The company relocated to Singapore’s Biopolis Biotech park and produced wound care products and first-aid kits for burns treatment. [5] [22]
In 2020, Carl Freer founded Cellvera, a company dedicated to the research and development of oral treatments for viral diseases. The firm expanded its operations through a licensing agreement with FujiFilm Toyama for the production and distribution of AVIGAN, a decision that contributed to a notable increase in revenue from $9 million in 2020 to an estimated $100 million in 2021. Cellvera's focus includes advancing treatments for various life-threatening viruses, reflecting its commitment to addressing global health challenges. [23] [24]
Freer founded Prepaire Labs as an effort to integrate artificial intelligence (AI) and data science into the drug development process. The initiative collaborates with academic and research institutions to apply advances in genome research, notably CRISPR technology. Prepaire Labs aims to optimize the drug development pipeline by facilitating target identification, lead discovery, optimization, drug synthesis, and pre-clinical testing, thereby seeking to enhance efficiency in developing treatments for various diseases. [25]
In February 2024, on behalf of Prepaire Labs, Freer entered into a strategic partnership with MGI, announced at MEDLAB Middle East 2024, aimed at advancing drug discovery and precision medicine. This collaboration marked the introduction of MGI's DNBSEQ-T20×2 sequencer to the Middle East, emphasizing the enhancement of genomics research and personalized medicine through advanced sequencing technology. [26]
Carl Freer has been granted several patents in the fields of technology and pharmaceuticals:
Freer has been arrested by police in Sweden, Spain, Germany, the UK and the USA. He has used aliases: Eric Jonsson and Brian Littleton. [31]
Freer's business partners, Stefan Eriksson and Mikael Ljungman, have both been convicted of fraud. [32]
Carl Freer was at the helm of Gizmondo Europe Limited during one of the biggest company fraud investigations in recent British history, totaling 215 million pounds (UK). [33]
In 2005, Freer was fined £135,000 by a court in Stuttgart, Germany for canceling check payments in a transaction with a car dealer. [10] Freer claimed he cancelled the cheques because he "thought he was being sold stolen cars". [1] [34] [35]
In 2006, no charges were filed after Los Angeles police found a collection of twelve rifles and four handguns at Freer's home in an investigation that led to his arrest on suspicion of impersonating a San Gabriel Valley Transit Authority police officer to buy a .44 Magnum handgun. Authorities dropped the investigation after Freer established that he did not impersonate a police officer and showed a valid gun permit. [10] [34] [36]
In 2009, the law firm Patton Boggs, on behalf of clients David Warnock and Simon Davies, filed an action alleging violations of the civil RICO Act against GetFugu, Carl Freer, and other officers and directors of GetFugu. [37] The firm followed the lawsuit with a press release that falsely claimed that GetFugu and Carl Freer were being investigated by the FBI. [38] In 2010, on a motion by GetFugu, District Court Judge George H. King dismissed Patton Boggs' claims with prejudice. [37] [39] GetFugu and Freer then countersued Patton Boggs for defamation and malicious prosecution, seeking damages of over $500 million. Patton Boggs filed a special motion to strike the defamation claim, contending that the press release regarding the alleged FBI investigation, even if false, was protected by litigation privilege, [37] [39] but the California Court of Appeals disagreed, allowing Freer and GetFugu to proceed with the $500 million lawsuit against Patton Boggs. [39] Patton Boggs' special motion to strike the malicious prosecution claim was also denied, holding that Patton Boggs did not have probable cause to prosecute the RICO claims. [37] [39]
In October 2015, Carl Freer unsuccessfully sued Danish Television Channel DR3 to have his name removed from a documentary on the Stein Bagger IT Factory fraud case prior to broadcast. [40] Following the documentary broadcast, he filed defamation claims against 5 employees of DR. [41]
In genetics, complementary DNA (cDNA) is DNA that was reverse transcribed from an RNA. cDNA exists in both single-stranded and double-stranded forms and in both natural and engineered forms.
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.
Rotaviruses are the most common cause of diarrhoeal disease among infants and young children. Nearly every child in the world is infected with a rotavirus at least once by the age of five. Immunity develops with each infection, so subsequent infections are less severe. Adults are rarely affected. Rotavirus is a genus of double-stranded RNA viruses in the family Reoviridae. There are nine species of the genus, referred to as A, B, C, D, F, G, H, I and J. Rotavirus A is the most common species, and these rotaviruses cause more than 90% of rotavirus infections in humans.
Chester Trent Lott Sr. is an American lobbyist, lawyer, author, and politician who represented Mississippi in the United States House of Representatives from 1973 to 1989 and in the United States Senate from 1989 to 2007. Lott served in numerous leadership positions in both chambers of Congress as one of the first of a wave of Republicans winning seats in Southern states that had been solidly Democratic. Later in his career, he served twice as Senate Majority Leader, and also, alternately, Senate Minority Leader. In 2003, he stepped down from the position after controversy due to his praising of Senator Strom Thurmond's 1948 segregationist Dixiecrat presidential bid.
A first aid kit or medical kit is a collection of supplies and equipment used to give immediate medical treatment, primarily to treat injuries and other mild or moderate medical conditions. There is a wide variation in the contents of first aid kits based on the knowledge and experience of those putting it together, the differing first aid requirements of the area where it may be used, and variations in legislation or regulation in a given area.
Sedoreoviridae is a family of double-stranded RNA viruses. Member viruses have a wide host range, including vertebrates, invertebrates, plants, protists and fungi. They lack lipid envelopes and package their segmented genome within multi-layered capsids. Lack of a lipid envelope has allowed three-dimensional structures of these large complex viruses to be obtained, revealing a structural and likely evolutionary relationship to the cystovirus family of bacteriophage. There are currently 97 species in this family, divided among 15 genera in two subfamilies. Reoviruses can affect the gastrointestinal system and respiratory tract. The name "reo-" is an acronym for "respiratory enteric orphan" viruses. The term "orphan virus" refers to the fact that some of these viruses have been observed not associated with any known disease. Even though viruses in the family Reoviridae have more recently been identified with various diseases, the original name is still used.
ClamAV (antivirus) is a free software, cross-platform antimalware toolkit able to detect many types of malware, including viruses. It was developed for Unix and has third party versions available for AIX, BSD, HP-UX, Linux, macOS, OpenVMS, OSF (Tru64), Solaris and Haiku. As of version 0.97.5, ClamAV builds and runs on Microsoft Windows. Both ClamAV and its updates are made available free of charge. One of its main uses is on mail servers as a server-side email virus scanner.
The Gizmondo is a handheld gaming console developed by Tiger Telematics. It was released in the UK, Sweden and the U.S. starting in March 2005. Its first-party games were developed in studios in Helsingborg, Sweden, and Manchester, England. Gizmondo Europe, Ltd. was based in London, England, and was a subsidiary of Florida-based Tiger Telematics, whose chairman Carl Freer led Gizmondo's development.
Squire Patton Boggs is an international law firm with over 40 offices in 20 countries. It was formed in 2014 by the merger of multinational law firm Squire Sanders with Washington, D.C. based Patton Boggs. It is one of the largest law firms in the world by total headcount and gross revenue, twelfth largest firm in the UK by revenue, and one of the top 12 by number of countries occupied.
Tiger Telematics, or Tiger, was a Swedish electronics company, best known for the failed Gizmondo handheld game console.
Richard Burns Rally is a sim racing game, published by SCi and developed by Warthog with advice of WRC champion Richard Burns (1971–2005).
Bo Stefan M. Eriksson is a Swedish video game developer and criminal from Uppsala involved in the British gaming company Gizmondo with his business partner Carl Freer, until it became insolvent in 2005. In February 2006, he became known for wrecking an Enzo Ferrari in Malibu, California, USA. He was the leader of the loose criminal organization "Uppsalamaffian" until he began to develop the Gizmondo.
Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). There is some evidence it may improve some ME/CFS symptoms.
Ronald Hans Anton Plasterk is a Dutch retired politician of the Labour Party (PvdA). He has a PhD degree in biology, specialising in molecular genetics. He is founder and CEO of Frame Cancer Therapeutics. He was appointed professor at the University of Amsterdam in September 2018.
Rabies is a viral disease that causes encephalitis in humans and other mammals. It was historically referred to as hydrophobia due to the symptom of panic when presented with liquids to drink. Early symptoms can include fever and abnormal sensations at the site of exposure. These symptoms are followed by one or more of the following symptoms: nausea, vomiting, violent movements, uncontrolled excitement, fear of water, an inability to move parts of the body, confusion, and loss of consciousness. Once symptoms appear, the result is virtually always death. The time period between contracting the disease and the start of symptoms is usually one to three months but can vary from less than one week to more than one year. The time depends on the distance the virus must travel along peripheral nerves to reach the central nervous system.
Mikael Ljungman is a Swedish politician, lawyer and businessman. He was 2009–2010 convicted of fraud and false accounting related to his business activities, for which he served a two-year prison term. He is also known for his association and involvement with two high-profile tech failures: the game console manufacturer Gizmondo in 2005 and IT Factory in 2008. After his release from prison, Ljungman became active in the Christian Democrats legal policy network. He was selected as a Christian Democrats parliamentary candidate for the 2014 Swedish elections, as number 32 on their Stockholm candidate list.
Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.
JK-05 is a broad-spectrum antiviral drug developed by the Chinese company Sihuan Pharmaceutical along with the Chinese Academy of Military Medical Sciences. It is reported to act as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication. In tests on mice, JK-05 was claimed to show efficacy against a range of RNA viruses, including influenza, Ebola virus and yellow fever, as well as several arenaviruses and bunyaviruses. The chemical structure of JK-05 has not been disclosed as of October 2014, but it is claimed to be a small molecule drug with a comparatively simple structure, which should be readily amenable to synthesis scale-up for mass production if testing is successful. The drug is however admitted to be similar to the Japanese anti-influenza drug favipiravir, developed by Fujifilm Holdings Corp, which has been used effectively to treat patients with Ebola. In addition, WHO committee members mentioned that the drug is a copy product of favipiravir, because patents of favipiravir were already registered in 2006 in China. The drug has been given preliminary approval by the Chinese authorities to be available for Chinese health workers involved in combating the 2014 West African Ebola outbreak, or if Ebola were to spread into mainland China. Several other Chinese developed antiviral drugs with anti-Ebola activity have also been disclosed, but have not progressed so far through development as JK-05.
Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID‑19 in those infected by SARS-CoV-2. It is taken by mouth.
Zhang Yongzhen, also known as Yong-Zhen Zhang, is a Chinese virologist known for his work relating to the COVID-19 pandemic. A professor at Fudan University, Zhang has discovered numerous RNA viruses and created a network of labs dedicated to monitoring new viruses. He led the team that sequenced and published the genome of SARS-CoV-2, the virus that causes COVID-19, in early January 2020.